Introgen Therapeutics Pursues Dual Listing on London Stock Exchange

Jun 06, 2005, 01:00 ET from Introgen Therapeutics, Inc.

    AUSTIN, Texas, June 6 /PRNewswire-FirstCall/ -- Introgen Therapeutics,
 Inc. (Nasdaq:   INGN) announced today that its management has been authorized to
 take steps to effect a dual listing for the company on both the NASDAQ and
 London Stock Exchange (LSE).
     The LSE listing decision reflects Introgen's ongoing discussions with
 potential international distribution partners, including European entities, as
 well as the expansion of its European investor base.  In December 2004,
 Introgen placed shares with European institutions to increase its already
 significant European investor base.  Introgen's first underwritten offering in
 1997 was sold exclusively to European institutions.
     In addition, the Company recently announced that it won an important and
 final European Patent Office case related to its p53 tumor suppressor therapy.
 The patent ruling results in a clear path to commercialization of several of
 Introgen's product candidates in Europe that utilize p53 as an active
 component, including ADVEXIN(R), INGN 225, INGN 234 and INGN 402.
     "A listing on the London Stock Exchange represents the next step in a
 series of actions that Introgen plans to take to leverage its assets on a
 global basis -- particularly in Europe and Asia.  ADVEXIN, as well as our
 other product candidates, represent first-in-class products aimed at treating
 cancer.  We want to maximize shareholder value with optimum commercial
 strategies around the world," said David Nance, Chief Executive Officer of
 Introgen.  "We are building a presence in Europe, having conducted some of our
 trials here and worked with European regulatory authorities on the global
 registration program for ADVEXIN.  In addition, we have developed a strong
 global patent portfolio.  We believe that a listing on the LSE demonstrates
 our commitment to facilitating investment in Introgen by European investors,
 as well as in developing a stronger European presence for the company."
     About Introgen
     Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the
 discovery, development and commercialization of targeted molecular therapies
 for the treatment of cancer and other diseases. Introgen is developing
 molecular therapeutics, immunotherapies, vaccines and nano-particle tumor
 suppressor therapies to treat a wide range of cancers using non-integrating
 tumor suppressors, cytokines and genes.  Introgen maintains integrated
 research, development, manufacturing, clinical and regulatory departments and
 operates a multiple manufacturing facilities including a commercial scale cGMP
 manufacturing facility.
     Certain statements in this press release that are not strictly historical
 may be "forward-looking" statements, which are based on current expectations
 and entail various risks and uncertainties. Such forward-looking statements
 include, but are not limited to, those relating to Introgen's future success
 with its clinical development programs for ADVEXIN for the treatment of cancer
 and the listing of Introgen's stock on the London Stock Exchange. There can be
 no assurance that Introgen will be able to commercially develop gene-based
 drugs, that necessary regulatory approvals will be obtained or that any
 clinical trials or studies undertaken will be successful or that the proposed
 treatments will prove to be safe and/or effective. The actual results may
 differ from those described in this press release due to risks and
 uncertainties that exist in Introgen's operations and business environment,
 including, but not limited to, Introgen's stage of product development and the
 limited experience in the development of gene-based drugs in general,
 Introgen's dependence upon proprietary technology and the current competitive
 environment, history of operating losses and accumulated deficits, reliance on
 collaborative relationships, and uncertainties related to clinical trials, the
 safety and efficacy of Introgen's product candidates, the ability to obtain
 the appropriate regulatory approvals, Introgen's patent protection and market
 acceptance, as well as other risks detailed from time to time in Introgen's
 filings with the Securities and Exchange Commission including its annual
 report on Form 10-K filed with the Securities and Exchange Commission on March
 15, 2005 and its quarterly report on Form 10-Q filed with the Securities and
 Exchange Commission on May 10, 2005. Introgen undertakes no obligation to
 publicly release the results of any revisions to any forward-looking
 statements that reflect events or circumstances arising after the date hereof.
     Editor's Note: For more information on Introgen Therapeutics, or for a
 menu of archived press releases, please visit Introgen's Website at:
      Introgen Therapeutics, Inc.
      C. Channing Burke
      (512) 708 9310 Ext. 322

SOURCE Introgen Therapeutics, Inc.